Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 25Gastrointestinal 20Thoracic 17Genitourinary 17CNS 13Dermatologic 11Sarcoma 10Breast 9Lymphoid 7Head & Neck 6Other hematologic neoplasm 4Endocrine 3Plasma cell 2Tumor-Agnostic 1Other solid neoplasm 1Myeloid 1

Conditions

Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin G × Other solid neoplasm × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡